AI English summary of an SEC filing — figures as filed
Regeneron Pharmaceuticals REGNRegeneron said U.S. net product sales of EYLEA HD and EYLEA rose from a year earlier in Q3 2024 and 9 months. In Q3, the company said, EYLEA HD wholesaler inventory increases had a $40 million effect, while EYLEA was hit by lower net selling prices.
Key points
AI summaryRegeneron said U.S. net product sales of EYLEA HD and EYLEA rose from a year earlier in Q3 2024 and 9 months. In Q3, the company said, EYLEA HD wholesaler inventory increases had a $40 million effect, while EYLEA was hit by lower net selling prices.
Regeneron said its share of Sanofi collaboration profits rose from a year earlier in Q3 2024 and 9 months, citing higher profits from Dupixent sales. It also said it earned the final $50.0 million sales-based milestone in Q3 2023.
Regeneron said it expects capital expenditures of $700 million to $740 million for 2024, mainly for expansion at its Tarrytown and Rensselaer facilities, including fill/finish capacity. In September 2024, it acquired a 1,100,000 square foot facility in Saratoga Springs.
Regeneron said proceeds from common stock issued on employee stock option exercises were $1.374 billion in the first 9 months of 2024. As of September 30, 2024, the remaining amount under the additional $3.0 billion share repurchase program approved in April 2024 was $2.893 billion.
Key figures
Quarter ended September 30, 2024
- Revenue
- $3.7B
- Operating income
- $1.2B
- Net income
- $1.3B
- EPS
- $11.54
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
U.S. EYLEA HD and EYLEA Sales Rise and Inventory Effect
Regeneron said U.S. net product sales of EYLEA HD and EYLEA rose from a year earlier in Q3 2024 and 9 months. In Q3, the company said, EYLEA HD wholesaler inventory increases had a $40 million effect, while EYLEA was hit by lower net selling prices.
Source · Based on the MD&A text of the filing
Higher Sanofi Profit Share and Final $50.0 million Milestone
Regeneron said its share of Sanofi collaboration profits rose from a year earlier in Q3 2024 and 9 months, citing higher profits from Dupixent sales. It also said it earned the final $50.0 million sales-based milestone in Q3 2023.
Source · Based on the MD&A text of the filing
2024 Capital Expenditure Outlook and Saratoga Springs Facility Acquisition
Regeneron said it expects capital expenditures of $700 million to $740 million for 2024, mainly for expansion at its Tarrytown and Rensselaer facilities, including fill/finish capacity. In September 2024, it acquired a 1,100,000 square foot facility in Saratoga Springs.
Source · Based on the MD&A text of the filing
Stock Issuance Proceeds and Remaining Buyback Authorization
Regeneron said proceeds from common stock issued on employee stock option exercises were $1.374 billion in the first 9 months of 2024. As of September 30, 2024, the remaining amount under the additional $3.0 billion share repurchase program approved in April 2024 was $2.893 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…